Background: Temozolomide and capecitabine (CAPTEM) chemotherapy is known to be active in patients with pancreatic neuroendocrine tumours. Objective: This retrospective analysis set out to describe the efficacy and toxicity of CAPTEM in patients with advanced pulmonary carcinoids (PCs). Methods: Patients were included with advanced PC who had been treated with a maximum of 6 cycles of oral temozolomide 200 mg/m2 on days 10–14 and capecitabine 750 mg/m2 b.i.d. on days 1–14, repeated every 28 days, -followed by monthly intramuscular injection of octreotide 30 mg long-acting release as maintenance treatment. Results: Of the 33 patients, all with well-differentiated PC, 61% had atypical carcinoid, 36% had Ki-67 index >10% and 42% had ≥3 organs involved by metastasis. CAPTEM was administered as first-line treatment in 42% of patients, and 17% had received prior somatostatin analogue treatment. Six patients (18%) achieved a partial response, 19 (58%) had stable disease and 8 (24%) developed progressive disease. After a median time of follow-up of 34.8 months, median progression-free survival (PFS) was 9.0 months and median overall survival 30.4 months. Median duration of disease response was 21.7 months and median duration of disease control 9.7 months. Patients with multi-organ metastasis had shorter PFS, but only when treated as second or third line with CAPTEM (p = 0.023). Conclusions: CAPTEM induced a modest response and PFS rate, comparable to other studies with temozolomide in patients with advanced PC. The efficacy of CAPTEM should be compared to that of monotherapy with temozolomide in a prospective clinical trial.

1.
Caplin
ME
,
Baudin
E
,
Ferolla
P
,
Filosso
P
,
Garcia-Yuste
M
,
Lim
E
, et al.
ENETS consensus conference participants. Pulmonary neuroendocrine (carcinoid) tumours: european Neuroendocrine Tumour Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids
.
Ann Oncol
.
2015
Aug
;
26
(
8
):
1604
20
.
[PubMed]
0923-7534
2.
Yao
JC
,
Fazio
N
,
Singh
S
,
Buzzoni
R
,
Carnaghi
C
,
Wolin
E
, et al.;
RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group
.
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
.
Lancet
.
2016
Mar
;
387
(
10022
):
968
77
.
[PubMed]
0140-6736
3.
Pavel
ME
,
Hainsworth
JD
,
Baudin
E
,
Peeters
M
,
Hörsch
D
,
Winkler
RE
, et al.;
RADIANT-2 Study Group
.
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
.
Lancet
.
2011
Dec
;
378
(
9808
):
2005
12
.
[PubMed]
0140-6736
4.
Ferolla
P
,
Brizzi
MP
,
Meyer
T
,
Mansoor
W
,
Mazieres
J
,
Do Cao
C
, et al.
Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial
.
Lancet Oncol
.
2017
Dec
;
18
(
12
):
1652
64
.
[PubMed]
1470-2045
5.
Ianniello
A
,
Sansovini
M
,
Severi
S
,
Nicolini
S
,
Grana
CM
,
Massri
K
, et al.
Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and (18)F-FDG PET
.
Eur J Nucl Med Mol Imaging
.
2016
Jun
;
43
(
6
):
1040
6
.
[PubMed]
1619-7070
6.
Brabander
T
,
van der Zwan
WA
,
Teunissen
JJ
,
Kam
BL
,
Feelders
RA
,
de Herder
WW
, et al.
Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors
.
Clin Cancer Res
.
2017
Aug
;
23
(
16
):
4617
24
.
[PubMed]
1078-0432
7.
Strosberg
JR
,
Fine
RL
,
Choi
J
,
Nasir
A
,
Coppola
D
,
Chen
DT
, et al.
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas
.
Cancer
.
2011
Jan
;
117
(
2
):
268
75
.
[PubMed]
0008-543X
8.
Eisenhauer
EA
,
Therasse
P
,
Bogaerts
J
,
Schwartz
LH
,
Sargent
D
,
Ford
R
, et al.
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
.
Eur J Cancer
.
2009
Jan
;
45
(
2
):
228
47
.
[PubMed]
0959-8049
9.
Papaxoinis
G
,
Lamarca
A
,
Quinn
AM
,
Mansoor
W
,
Nonaka
D
.
Clinical and Pathologic Characteristics of Pulmonary Carcinoid Tumors in Central and Peripheral Locations
.
Endocr Pathol
.
2018
Sep
;
29
(
3
):
259
68
. ;
Epub ahead of print
.
[PubMed]
1046-3976
10.
World Medical Association
.
World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects
.
JAMA
.
2013
Nov
;
310
(
20
):
2191
4
.
[PubMed]
0098-7484
11.
Fazio
N
,
Buzzoni
R
,
Delle Fave
G
,
Tesselaar
ME
,
Wolin
E
,
Van Cutsem
E
, et al.
Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis
.
Cancer Sci
.
2018
Jan
;
109
(
1
):
174
81
.
[PubMed]
1347-9032
12.
Fazio
N
,
Granberg
D
,
Grossman
A
,
Saletan
S
,
Klimovsky
J
,
Panneerselvam
A
, et al.
Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study
.
Chest
.
2013
Apr
;
143
(
4
):
955
62
.
[PubMed]
0012-3692
13.
Liu
Q
.
Zhang, Luo P, Dou J, Tan H. (2017). Clinical observation of capecitabine and temozolomide in the treatment of advanced pancreatic neuroendocrine tumours
.
Chin J Clin Oncol
.
2017
;
44
:
228
32
.1672-7118
14.
Saif
MW
,
Kaley
K
,
Brennan
M
,
Garcon
MC
,
Rodriguez
G
,
Rodriguez
T
.
A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy
.
JOP
.
2013
Sep
;
14
(
5
):
498
501
.
[PubMed]
1590-8577
15.
Crespo
G
,
Jiménez-Fonseca
P
,
Custodio
A
,
López
C
,
Carmona-Bayonas
A
,
Alonso
V
, et al.
Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience
.
Future Oncol
.
2017
Mar
;
13
(
7
):
615
24
.
[PubMed]
1479-6694
16.
Chatzellis
E
,
Angelousi
A
,
Daskalakis
K
,
Tsoli
M
,
Alexandraki
KI
,
Wachuła
E
, et al.
Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms
.
Neuroendocrinology
.
2019
Jun
;
•••
: ;
Epub ahead of print
.
[PubMed]
0028-3835
17.
de Mestier
L
,
Walter
T
,
Evrard
C
,
de Boissieu
P
,
Hentic
O
,
Cros
J
, et al.
Temozolomide alone or combined to capecitabine for the treatment of advanced pancreatic NET
.
Neuroendocrinology
.
2019
May
;
•••
: ;
Epub ahead of print
.
[PubMed]
0028-3835
18.
Kunz
PL
,
Catalano
PJ
,
Nimeiri
H
,
Fisher
GA
,
Longacre
TA
,
Suarez
CJ
, et al.
A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumours: A trial of the ECOG-ACRIN Cancer Research Group (E2211). Journal of Clinical Oncology
2018
36:15_suppl, 4004-4004.
19.
Granberg
D
,
Eriksson
B
,
Wilander
E
,
Grimfjärd
P
,
Fjällskog
ML
,
Oberg
K
, et al.
Experience in treatment of metastatic pulmonary carcinoid tumors
.
Ann Oncol
.
2001
Oct
;
12
(
10
):
1383
91
.
[PubMed]
0923-7534
20.
Chong
CR
,
Wirth
LJ
,
Nishino
M
,
Chen
AB
,
Sholl
LM
,
Kulke
MH
, et al.
Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors
.
Lung Cancer
.
2014
Nov
;
86
(
2
):
241
6
.
[PubMed]
0169-5002
21.
Crona
J
,
Fanola
I
,
Lindholm
DP
,
Antonodimitrakis
P
,
Öberg
K
,
Eriksson
B
, et al.
Effect of temozolomide in patients with metastatic bronchial carcinoids
.
Neuroendocrinology
.
2013
;
98
(
2
):
151
5
.
[PubMed]
0028-3835
22.
Bello Roufai
D
,
Planchard
D
,
Walter
T
,
Berdelou
A
,
Guigay
J
,
Souquet
PJ
, et al.
Antitumour Efficacy of Temozolomide in Patients with Metastatic Pulmonary Carcinoids
.
Neuroendocrinology
.
2016
;
103
suppl 1
:
65
.0028-3835
23.
Tabaksblat
E
,
Ladekarl
M
.
Temozolomide-Based Second-Line Chemotherapy in Patients with Advanced Bronchopulmonary Neuroendocrine Tumours
.
Neuroendocrinology
.
2016
;
103
suppl 1
:
72
.0028-3835
24.
Cives
M
,
Ghayouri
M
,
Morse
B
,
Brelsford
M
,
Black
M
,
Rizzo
A
, et al.
Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors
.
Endocr Relat Cancer
.
2016
Sep
;
23
(
9
):
759
67
.
[PubMed]
1351-0088
25.
Hegi
ME
,
Diserens
AC
,
Gorlia
T
,
Hamou
MF
,
de Tribolet
N
,
Weller
M
, et al.
MGMT gene silencing and benefit from temozolomide in glioblastoma
.
N Engl J Med
.
2005
Mar
;
352
(
10
):
997
1003
.
[PubMed]
0028-4793
26.
Cros
J
,
Hentic
O
,
Rebours
V
,
Zappa
M
,
Gille
N
,
Theou-Anton
N
, et al.
MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors
.
Endocr Relat Cancer
.
2016
Aug
;
23
(
8
):
625
33
.
[PubMed]
1351-0088
27.
Owen
DH
,
Alexander
AJ
,
Konda
B
,
Wei
L
,
Hemminger
JA
,
Schmidt
CR
, et al.
Combination therapy with capecitabine and temozolomide in patients with low and high grade neuroendocrine tumors, with an exploratory analysis of O6-methylguanine DNA methyltransferase as a biomarker for response
.
Oncotarget
.
2017
Oct
;
8
(
61
):
104046
56
.
[PubMed]
1949-2553
28.
Campana
D
,
Walter
T
,
Pusceddu
S
,
Gelsomino
F
,
Graillot
E
,
Prinzi
N
, et al.
Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study
.
Endocrine
.
2018
Jun
;
60
(
3
):
490
8
.
[PubMed]
1355-008X
29.
Kulke
MH
,
Hornick
JL
,
Frauenhoffer
C
,
Hooshmand
S
,
Ryan
DP
,
Enzinger
PC
, et al.
O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors
.
Clin Cancer Res
.
2009
Jan
;
15
(
1
):
338
45
.
[PubMed]
1078-0432
30.
Lei
L
,
Jiang
Z
,
Zhang
G
,
Cheng
Q
,
Lu
H
.
MGMT promoter methylation and 1p/19q co-deletion of surgically resected pulmonary carcinoid and large-cell neuroendocrine carcinoma
.
World J Surg Oncol
.
2018
Jun
;
16
(
1
):
110
.
[PubMed]
1477-7819
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.